Literature DB >> 25127862

The expression of sphingosine-1 phosphate receptor-1 in chronic lymphocytic leukemia cells is impaired by tumor microenvironmental signals and enhanced by piceatannol and R406.

Mercedes Borge1, Federico Remes Lenicov2, Paula R Nannini3, María M de los Ríos Alicandú3, Enrique Podaza1, Ana Ceballos2, Horacio Fernández Grecco4, María Cabrejo4, Raimundo F Bezares5, Pablo E Morande6, Pablo Oppezzo6, Mirta Giordano1, Romina Gamberale7.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the progressive accumulation of clonal B lymphocytes. Proliferation occurs in lymphoid tissues upon interaction of leukemic cells with a supportive microenvironment. Therefore, the mobilization of tissue-resident CLL cells into the circulation is a useful therapeutic strategy to minimize the reservoir of tumor cells within survival niches. Because the exit of normal lymphocytes from lymphoid tissues depends on the presence of sphingosine-1 phosphate (S1P) and the regulated expression of S1P receptor-1 (S1PR1), we investigated whether the expression and function of S1PR1 can be modulated by key microenvironment signals. We found that activation of CLL cells with CXCL12, fibroblast CD40L(+), BCR cross-linking, or autologous nurse-like cells reduces their S1PR1 expression and the migratory response toward S1P. Moreover, we found that S1PR1 expression was reduced in the proliferative/activated subset of leukemic cells compared with the quiescent subset from the same patient. Similarly, bone marrow-resident CLL cells expressing high levels of the activation marker CD38 showed a lower expression of S1PR1 compared with CD38(low) counterparts. Finally, given that treatment with BCR-associated kinase inhibitors induces a transient redistribution of leukemic cells from lymphoid tissues to circulation, we studied the effect of the Syk inhibitors piceatannol and R406 on S1PR1 expression and function. We found that they enhance S1PR1 expression in CLL cells and their migratory response toward S1P. Based on our results, we suggest that the regulated expression of S1PR1 might modulate the egress of the leukemic clone from lymphoid tissues.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25127862     DOI: 10.4049/jimmunol.1400547

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

2.  Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells.

Authors:  María Belén Almejún; Mercedes Borge; Ana Colado; Esteban Enrique Elías; Enrique Podaza; Denise Risnik; Carlos Daniel De Brasi; Carmen Stanganelli; Irma Slavutsky; María Cabrejo; Horacio Fernández-Grecco; Raimundo Fernando Bezares; Santiago Cranco; Rubén Ángel Burgos; Julio César Sánchez-Ávalos; Pablo Oppezzo; Mirta Giordano; Romina Gamberale
Journal:  Haematologica       Date:  2017-03-30       Impact factor: 9.941

Review 3.  S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.

Authors:  Narges Rostami; Afshin Nikkhoo; Amir Ajjoolabady; Gholamreza Azizi; Mohammad Hojjat-Farsangi; Ghasem Ghalamfarsa; Bahman Yousefi; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

4.  Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.

Authors:  Kathleen J Till; Andrew R Pettitt; Joseph R Slupsky
Journal:  J Immunol       Date:  2015-01-28       Impact factor: 5.422

Review 5.  Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies.

Authors:  Kazuyuki Kitatani; Makoto Taniguchi; Toshiro Okazaki
Journal:  Mol Cells       Date:  2015-05-22       Impact factor: 5.034

6.  To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients.

Authors:  Jaroslaw Piszcz; Emily G Armitage; Alessia Ferrarini; Francisco J Rupérez; Agnieszka Kulczynska; Lukasz Bolkun; Janusz Kloczko; Adam Kretowski; Alina Urbanowicz; Michal Ciborowski; Coral Barbas
Journal:  Oncotarget       Date:  2016-04-19

7.  Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

Authors:  Jack W Singer; Suliman Al-Fayoumi; Haiching Ma; Rami S Komrokji; Ruben Mesa; Srdan Verstovsek
Journal:  J Exp Pharmacol       Date:  2016-08-16

8.  Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia.

Authors:  Stéphane Saint-Georges; Maude Quettier; Marouane Bouyaba; Stéphanie Le Coquil; Vanessa Laurienté; Lionel Guittat; Vincent Lévy; Florence Ajchenbaum-Cymbalista; Nadine Varin-Blank; Christine Le Roy; Dominique Ledoux
Journal:  Oncotarget       Date:  2016-07-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.